î
îŒ
î
Genmab A/S
GMAB33.420USD
-0.300-0.89%
çµå€Â 12/26, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
20.58Bæ䟡ç·é¡
14.14çŽè¿12ã¶æPER
î
詳现æ å ± Genmab A/S äŒæ¥å
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/Sã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãGMAB
äŒç€ŸåGenmab A/S
äžå Žæ¥Oct 01, 2000
æé«çµå¶è²¬ä»»è
ãCEOãVan De Winkel (Jan G.J)
åŸæ¥å¡æ°2682
蚌åžçš®é¡Depository Receipt
決ç®ææ«Oct 01
æ¬ç€Ÿæåšå°Carl Jacobsens Vej 30
éœåžVALBY
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœDenmark
éµäŸ¿çªå·2500
é»è©±çªå·4570202728
ãŠã§ããµã€ãhttps://www.genmab.com/
äŒæ¥ã³ãŒãGMAB
äžå Žæ¥Oct 01, 2000
æé«çµå¶è²¬ä»»è
ãCEOãVan De Winkel (Jan G.J)
Genmab A/Sã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
åçå èš³
é貚: USDæŽæ°æå»: Mon, Oct 6
é貚: USDæŽæ°æå»: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
æ ªäž»
æŽæ°æå»: Mon, Nov 17
æŽæ°æå»: Mon, Nov 17
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
ä»ã®
94.64%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
ä»ã®
94.64%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor/Hedge Fund
4.59%
Investment Advisor
3.46%
Hedge Fund
1.96%
Research Firm
0.19%
Pension Fund
0.03%
Bank and Trust
0.02%
Family Office
0.01%
Venture Capital
0.01%
ä»ã®
89.71%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Orbis Investment Management Ltd.
7.92M
1.29%
+2.21M
+38.69%
Jun 30, 2025
AllianceBernstein L.P.
10.66M
1.73%
-4.06M
-27.59%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
3.45M
0.56%
+2.08M
+152.25%
Jun 30, 2025
Harding Loevner LP
2.92M
0.48%
+42.61K
+1.48%
Jun 30, 2025
Two Sigma Investments, LP
3.44M
0.56%
-433.92K
-11.20%
Jun 30, 2025
Renaissance Technologies LLC
2.77M
0.45%
+504.40K
+22.30%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.50M
0.41%
-443.29K
-15.04%
Jun 30, 2025
First Trust Advisors L.P.
1.77M
0.29%
+60.50K
+3.54%
Jun 30, 2025
Parametric Portfolio Associates LLC
1.19M
0.19%
-6.41K
-0.54%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
詳现ãèŠã
Tema Oncology ETF
æ¯ç4.2%
First Trust NYSE Arca Biotechnology Index Fund
æ¯ç3.02%
WisdomTree BioRevolution Fund
æ¯ç1.31%
iShares Biotechnology ETF
æ¯ç1.15%
AB Disruptors ETF
æ¯ç0.69%
JPMorgan Healthcare Leaders ETF
æ¯ç0.28%
First Trust NASDAQ BuyWrite Income ETF
æ¯ç0.26%
ProShares Ultra Nasdaq Biotechnology
æ¯ç0.12%
Invesco Nasdaq Biotechnology ETF
æ¯ç0.12%
ActivePassive International Equity ETF
æ¯ç0.12%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
Genmab A/Sã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îGenmab A/Sã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
Orbis Investment Management Ltd.ã¯7.92Mæ ªãä¿æããŠãããããã¯å šäœã®1.29%ã«çžåœããŸãã
AllianceBernstein L.P.ã¯10.66Mæ ªãä¿æããŠãããããã¯å šäœã®1.73%ã«çžåœããŸãã
Arrowstreet Capital, Limited Partnershipã¯3.45Mæ ªãä¿æããŠãããããã¯å šäœã®0.56%ã«çžåœããŸãã
Harding Loevner LPã¯2.92Mæ ªãä¿æããŠãããããã¯å šäœã®0.48%ã«çžåœããŸãã
Two Sigma Investments, LPã¯3.44Mæ ªãä¿æããŠãããããã¯å šäœã®0.56%ã«çžåœããŸãã
Orbis Investment Management Ltd.ã¯7.92Mæ ªãä¿æããŠãããããã¯å šäœã®1.29%ã«çžåœããŸãã
AllianceBernstein L.P.ã¯10.66Mæ ªãä¿æããŠãããããã¯å šäœã®1.73%ã«çžåœããŸãã
Arrowstreet Capital, Limited Partnershipã¯3.45Mæ ªãä¿æããŠãããããã¯å šäœã®0.56%ã«çžåœããŸãã
Harding Loevner LPã¯2.92Mæ ªãä¿æããŠãããããã¯å šäœã®0.48%ã«çžåœããŸãã
Two Sigma Investments, LPã¯3.44Mæ ªãä¿æããŠãããããã¯å šäœã®0.56%ã«çžåœããŸãã
Genmab A/Sã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îGenmab A/Sã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
Orbis Investment Management Ltd.
AllianceBernstein L.P.
Paradigm BioCapital Advisors LP
Orbis Investment Management Ltd.
AllianceBernstein L.P.
Paradigm BioCapital Advisors LP
Genmab A/SïŒGMABïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãGenmab A/Sã®æ ªåŒãä¿æããŠããæ©é¢ã¯515瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ64.81Mã§ãå
šäœã®10.54%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯0.23%å¢å ããŠããŸãã
Genmab A/Sã®æ倧ã®åçæºã¯äœã§ããïŒ
îFY2025Q2ã«ãããŠãRoyaltieséšéãGenmab A/Sã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯789.00Mã§ãå
šåçã®85.30%ãå ããŠããŸãã
